# Fractyl Health, Inc > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Fractyl Health, Inc). ## Overview Fractyl Health is a U.S.-based metabolic therapeutics company developing device and gene-therapy approaches for obesity and type 2 diabetes. Its lead platform, Revita, is an endoscopic duodenal mucosal resurfacing procedure designed to modify disease biology, while its Rejuva program explores pancreas-targeted gene therapy for longer-duration metabolic treatment. ## Products & services • Revita DMR endoscopic procedure for metabolic disease • Revita single-use disposable catheter components • Rejuva pancreas-targeted gene therapy platform • REMAIN weight-maintenance clinical program • REVEAL-1 cohort and related clinical data generation - **Revita DMR system** (0%) — Endoscopic duodenal mucosal resurfacing procedure and related disposable components used to treat metabolic disease. - **Rejuva gene therapy platform** (0%) — Preclinical and clinical gene-therapy candidates intended to address the root causes of obesity and T2D. - **Clinical development programs** (0%) — Pivotal studies, registries, and follow-up programs that generate evidence for regulatory and payer adoption. - **Commercialization infrastructure** (0%) — Sales, marketing, medical affairs, distribution, and manufacturing capabilities being built for future launch. - Revita DMR endoscopic procedure for obesity and T2D - Single-use Revita catheter and disposable procedure components - Rejuva gene therapy candidates for metabolic disease - Clinical development programs such as REMAIN and REVEAL-1 - Manufacturing and commercialization infrastructure for future launch ## Customers Fractyl does not yet have approved commercial products in the U.S., so its near-term customers are clinical investigators, physicians, and study sites involved in its trials and registries. If approved, its end customers would be diabetologists, endocrinologists, gastroenterologists, interventional endoscopists, hospitals, and payors evaluating the clinical and economic value of Revita and, later, Rejuva-based therapies. - **Physicians treating metabolic disease** (primary) — Diabetologists, endocrinologists, PCPs, gastroenterologists, and endoscopists who would use or refer patients for Revita because it offers a disease-modifying approach. - **Hospitals and procedure centers** (primary) — Facilities that would buy the procedure workflow, disposables, and related support if the therapy is commercialized. - **Third-party payors** (primary) — Commercial and public payors that determine reimbursement and therefore adoption economics for Revita. - **Clinical investigators and trial sites** (secondary) — Research centers enrolling patients in REMAIN, REVEAL-1, and registry studies to validate safety and efficacy. - Physicians in diabetes and metabolic disease care who may adopt Revita - Interventional endoscopists and gastroenterologists using the procedure - Hospitals and procedure centers that would purchase and deploy the system - Third-party payors that decide whether to cover the procedure - Clinical trial sites and investigators supporting evidence generation ## Geography Fractyl is headquartered in the United States and currently has no approved product sales there. The company’s disclosed clinical evidence includes a Germany real-world registry study, indicating some operational and data-generation exposure outside the U.S., but the business remains overwhelmingly U.S.-centric at this stage. - Headquartered in the United States - No approved U.S. product sales yet - Clinical evidence includes a Germany real-world registry - Commercial build-out is focused on future U.S. launch - Manufacturing and sterilization rely partly on third parties ## Strategy Fractyl’s strategy is to complete clinical development, secure regulatory approvals, and build the commercial infrastructure needed to launch Revita and later Rejuva. The company is also trying to validate a consumables-based model and generate payer acceptance by showing durable clinical benefit and favorable procedure economics. - **Complete pivotal and follow-up clinical programs** (short-term) — Regulatory approval and physician adoption depend on robust safety and efficacy data. - **Build commercialization infrastructure** (short-term) — The company needs sales, marketing, medical affairs, and distribution capabilities before launch. - **Secure reimbursement and payer acceptance** (medium-term) — Coverage decisions will determine whether Revita can scale economically after approval. - **Transition to a recurring consumables model** (medium-term) — Management expects future revenue streams to depend on repeat procedure economics and consumable usage. - Advance REMAIN and REVEAL-1 to support approval and adoption - Build sales, marketing, medical affairs, and distribution capabilities - Demonstrate clinical utility and economic value to payors - Develop a consumables-based commercial model for recurring revenue - Expand manufacturing readiness for future commercialization ## Risks Fractyl is a development-stage company with no approved U.S. products, so its business depends on successful clinical outcomes, regulatory clearance, and future reimbursement. It also faces financing, manufacturing-supply, and commercialization execution risk, while competing against larger medical device, diabetes, and biopharma companies with stronger resources and established channels. - **Clinical development failure** [critical] — The company has not completed pivotal studies, so adverse data could prevent approval and commercialization. - **Financing and going-concern pressure** [high] — The company expects continued operating losses and negative cash flow until product sales begin, requiring additional capital. - **Reimbursement and payer adoption risk** [high] — Even with approval, payors may require more evidence or decline coverage, limiting uptake. - **Manufacturing and supply-chain dependence** [high] — Key components and sterilization are outsourced, and some materials are single-sourced, which can disrupt trials or launch. - **Competitive pressure** [medium] — Larger competitors may offer safer, cheaper, or more established alternatives and can outspend Fractyl on commercialization. - No approved U.S. products, so revenue depends on future approvals - Clinical trials may fail to show safety, efficacy, or durability - Payors may refuse coverage without more evidence - Commercial launch requires costly sales and distribution build-out - Third-party manufacturing and single-source inputs create supply risk ## Accounting Fractyl’s reporting is dominated by development-stage estimates rather than product revenue recognition, because it has no approved U.S. sales. Investors should watch warrant-liability valuation, stock-based compensation, clinical-trial accruals, and going-concern-related disclosures, since these can materially affect reported losses and balance-sheet volatility. - **Warrant liabilities** — Can create non-cash gains or losses in the income statement - **Clinical trial accruals** — Affects R&D expense timing and comparability - **Stock-based compensation** — Raises reported operating costs without immediate cash outflow - **Going concern and liquidity** — Shapes balance-sheet and cash-flow interpretation - No product revenue yet, so results are driven by R&D and G&A spending - Warrant liabilities require fair-value remeasurement and can create volatility - Clinical trial and vendor accruals depend on management estimates - Stock-based compensation affects operating loss and equity dilution - Going-concern and liquidity disclosures are important for interpretation --- *Last updated: 2026-09-24T11:46:33.883209+00:00*